Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMC

Cannabis improves metabolic dysfunction and macrophage signatures in obese mice

VanderVeen BN., Cardaci TD., Unger CA., NeSmith MM., Freeman JC., Bastian AV.

Animal Study with a reported sample of 15 on Type 2 Diabetes, published in Am J Physiol Cell Physiol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Am J Physiol Cell Physiol (2025)
Reported sample size
15
Source database
Europe PMC
PMID
40960937
PMCID
PMC12914386
DOI
10.1152/ajpcell.00503.2025
Citations
2

Abstract (original English)

Obesity rates continue to rise, highlighting the need for new treatments that are effective, safe, and widely accessible. Aligned with the easing of restrictions on cannabis use, interest in its therapeutic potential is evolving. As such, we examined the effects of the cannabis plant with high cannabidiol (CBD) content or high Δ 9 -tetrahydrocannabinol (THC) content on metabolic and immune dysregulation in obese mice. Briefly, female C57BL/6 mice were randomized into four groups ( n = 15/group): 1 ) lean, 2 ) obese placebo, 3 ) obese CBD, and 4 ) obese THC. Lean mice consumed a low-fat diet for the study duration. Obese mice consumed a high-fat diet for 16 wk before a 4-wk cannabis (3 times/wk; high CBD = ∼4.2 mg/kg and high THC = ∼7.3 mg/kg) intervention. Consistent with our hypothesis, obesity increased homeostasis model assessment of insulin resistance (HOMA-IR) and metabolic dysfunction-associated steatohepatitis (MASH), both of which were significantly mitigated by either high (10.5%) CBD or high (18.16%) THC cannabis ( P P NEW & NOTEWORTHY We examined the effects of the cannabis plant with high cannabidiol (CBD) content or high Δ 9 -tetrahydrocannabinol (THC) content on metabolic and immune dysregulation in obese mice. Both CBD and THC mitigated the obesity-induced increase in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) and metabolic dysfunction-associate

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
LiverMacrophagesAnimalsMice, Inbred C57BLMiceMice, ObeseCannabisInsulin ResistanceObesityCannabidiol

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research